Compare Norfolk Southern Corporation (NSC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Norfolk Southern Corporation trades at $333 (market cap $75.23B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Norfolk Southern Corporation is far larger — about 49.2× Recursion Pharmaceuticals Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NSC | RXRX | |
|---|---|---|
Market Cap | $75.23B | $1.53B |
Sector | Technology | Health |
52-Week High | $340.16 | $6.79 |
52-Week Low | $272.35 | $2.84 |
Enterprise Value | $90.99B | $946.50M |
Dividend Yield | 1.61% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
